Welcome to our dedicated page for Silence Therapeutics Plc news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc stock.
Silence Therapeutics plc (Nasdaq: SLN) generates a steady flow of news as a global clinical-stage biotechnology company developing siRNA (short interfering RNA) therapies. Its updates focus on the progress of programs built on its proprietary mRNAi GOLD™ platform, which is designed to create precision engineered siRNAs that target and silence disease-associated genes in the liver.
Investors following SLN news can expect detailed coverage of clinical trial milestones, particularly for divesiran, the company’s first-in-class siRNA candidate for polycythemia vera (PV). Recent announcements describe additional Phase 1 data presented at major hematology meetings, durable hematocrit control and reduced need for phlebotomies in PV patients, and the completion of enrollment in the global, randomized SANRECO Phase 2 study.
Silence also issues news on its broader pipeline and strategy, including updates on zerlasiran for cardiovascular disease, extra-hepatic siRNA targeting work, and its collaboration program SLN312 licensed to AstraZeneca. Financial result press releases provide context on research and development spending, cash and investment balances, and the company’s stated cash runway expectations, alongside commentary on operational priorities.
Corporate governance and leadership developments feature in SLN news as well, such as changes to the Board of Directors, executive transitions and outcomes of shareholder votes at the annual general meeting. Conference participation announcements highlight company presentations at healthcare and investor events, where management discusses the siRNA platform, clinical data and pipeline priorities.
By monitoring this news page, readers can review a chronological record of Silence Therapeutics’ clinical, financial and corporate disclosures related to SLN, with an emphasis on the evolution of its siRNA programs in cardiovascular disease, hematology and rare diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Silence Therapeutics plc (NASDAQ: SLN) will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2 at 3:30 p.m. ET. This event highlights Silence's commitment to innovative biotechnology aimed at silencing diseases through precision-engineered medicines. The presentation will be available via a live webcast on the Company’s website, with an archived replay accessible afterward. Silence Therapeutics specializes in RNA interference to develop medicines targeting genetic expressions involved in disease pathologies. Notable product candidates include SLN360 for reducing cardiovascular risk and SLN124 for hematological disorders. The Company collaborates with leading pharmaceutical companies like AstraZeneca and Mallinckrodt Pharmaceuticals.
Silence Therapeutics, a biotechnology company, announced the publication of preclinical data in the journal Blood linking iron regulation to polycythemia vera (PV) and supporting the therapeutic potential of SLN124. The authors, including researchers from WEHI, found variants of the iron-regulating gene HFE in a study of 440 PV cases versus over 400,000 controls. The findings suggest SLN124, an siRNA targeting TMPRSS6, may help control red blood cell production in PV by increasing hepcidin levels. Currently undergoing SANRECO phase 1/2 trials, SLN124 has rare pediatric disease, orphan drug, and FDA Fast Track designations for PV.
Silence Therapeutics plc (NASDAQ: SLN) announces management's participation in a virtual fireside chat at Guggenheim’s Genomic Medicines and Rare Disease Days on April 4th, 2023, at 2:10 p.m. ET. A live webcast will be accessible through the Investors section of Silence's website, with an archived replay available post-conference. Silence Therapeutics focuses on developing innovative medicines using RNA interference (RNAi) to target disease-related genes. Notable products include SLN360 for cardiovascular risk and SLN124 for hematological diseases. Collaborations with AstraZeneca and others enhance Silence’s research capabilities.
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has announced the appointment of Barbara A. Ruskin, Ph.D, J.D., to its Board of Directors, expanding the board to nine members. Dr. Ruskin, who has over 25 years of experience in life sciences and intellectual property law, previously served as Chief Intellectual Property and Innovation Officer at Silence Therapeutics (OTC: SLNCF). Her background includes advising pharmaceutical companies and managing patent portfolios for major biotech firms. The company is focused on developing non-addictive pain management products and is seeking FDA approval for its candidates.